Compare KLTR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | MXCT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.6M | 160.0M |
| IPO Year | 2021 | 2021 |
| Metric | KLTR | MXCT |
|---|---|---|
| Price | $1.39 | $0.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.50 | ★ $7.50 |
| AVG Volume (30 Days) | 300.6K | ★ 1.4M |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $178,717,000.00 | $38,627,000.00 |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $1.08 | $9.64 |
| P/E Ratio | $19.50 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $1.21 | $0.64 |
| 52 Week High | $2.29 | $3.58 |
| Indicator | KLTR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 41.02 |
| Support Level | N/A | $0.75 |
| Resistance Level | $1.68 | $1.79 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 41.94 | 91.44 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.